Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    

| More

Shree Cement - Q1FY21 Result Update - ICICI Securities

Posted On: 2020-08-12 09:14:59

Shree Cement's operational performance in Q1FY21 broadly remained in line with our estimates while beating our estimates at the PAT level due to higher other income. On the operational front, volumes fell 18.6% YoY to 4.9 MT (vs. I-direct estimate of 4.8 MT) as volume sales were affected from end of March to April 2020 due to lockdown. Blended realisations also remained weak, declining 5.8% YoY to Rs. 4,718/t (vs. I-direct estimate of Rs. 4,782/t). EBITDA for the quarter fell 22.3% YoY to Rs. 700.7 crore, driven by lower sales volumes and realisations. However, it remained above our estimated EBITDA of Rs. 652 crore. Blended EBITDA/t for Q1FY21 was at Rs. 1,421/t, down 4.5% YoY (vs. I-direct estimate of Rs. 1,361/t). Other income was up 143% to Rs. 124 crore led by interest income from recent fund raising through QIP (Rs. 2400 crore) that has not been deployed towards any capex yet. This, along with a sharp fall in depreciation charge (down 32.6% YoY to Rs. 271 crore) led the company to report better than estimated net profit of Rs. 370.8 crore (up 2.1% YoY) vs. I-direct estimated PAT of Rs. 155.6 crore.

Valuation & Outlook

Shree Cement has added capacities by entering non-core regions without jeopardising its profitability and return ratios. We expect the company to continue its leadership in costs. This would, in turn, help it to consistently gain the market share with improved profitability and return matrix. Thus, it remains a long term structural play. Hence, we maintain our BUY rating on the stock with a revised TP of Rs. 25,000/share (21.5x FY22E EV/EBITDA).

For details, click on the link below:

Shares of SHREE CEMENT LTD. was last trading in BSE at Rs.21388.85 as compared to the previous close of Rs. 21538.95. The total number of shares traded during the day was 2255 in over 860 trades.

The stock hit an intraday high of Rs. 21629.55 and intraday low of 21282.95. The net turnover during the day was Rs. 48289719.

Source: Equity Bulls

Click here to send ur comments or to

Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only., its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.

Other Headlines:

Zydus Wellness - Leadership in niche categories; initiate at BUY - ICICI Securities

Power - Setting the stage - ICICI Securities

Company Update - Elgi Equipments - ICICI Securities

Nano Nivesh - The Anup Engineering - ICICI Securities

RBI OMO announcement of Rs. 10000 crore - Angel Broking

TCS deal win - Sep 24, 2020 - Angel Broking

View on Pre-Monetary Policy by Upasna Bhardwaj, Senior Economist at Kotak Mahindra Bank

US FDA approval to Zydus Cadila - Angel Broking

HDFC Securities Institutional Research Desk: Cement Sector Thematic - Spotting the sweet spot

Bharat Forge - Expectation hurdle remains steep - ICICI Securities


Mutual Fund Review - September, 2020 - ICICI Securities

UTI AMC announces IPO date - Angel Broking

Asian Paints - Mr. Amarjeet Maurya - AVP - Mid Caps, Angel Broking Ltd

Britannia Industries - Mr. Amarjeet Maurya - AVP - Mid Caps, Angel Broking Ltd

Hexaware Technologies (Not Rated): Hexaware accepts 475/share as final delisting price - ICICI Securities

CAMS IPO - Day 2 Subscription - Angel Boking

Chemcon Speciality Chemicals - IPO subscribed 12.62 times on second day - Angel Broking

General insurance - Fire, health remain growth drivers, rising Covid claims a concern - ICICI Securities

Supreme Industries - Perfect recipe for rerating; upgrade to BUY - ICICI Securities

Titan Company - Best positioned to gain from faster-than-expected recovery. Upgrade to ADD - ICICI Securities

Sector Update - Telecom - Sep 23, 2020 - ICICI Securities

Allcargo Logistics - Highlights of Blackstone deal - ICICI Securities

I-direct Instinct - Gokaldas Exports

Economy: RBI's trilemma: allows for INR strength - Kotak

HCL Technologies - Company Update - ICICI Securities

Chemcon Speciality Chemicals - IPO Review - ICICI Securities

Angel Broking - IPO Note - YES Securities

TCS - Announcement of its blockhchain based solutions on Microsoft Azure - Angel Broking

Amber Enterpirses acquire Sidwal - Angel Broking

Dixon Technologies - Buy - YES Securities

HCL Technologies acquisition of DWS Limited - Angel Broking

Allcargo Logistics CFO Resignation - Angel Broking

Upgrade to BUY on Gateway Distriparks - Strengthening the balance sheet - HDFC Securities

BUY on ITD Cementation - Execution pickup awaited - HDFC Securities

Allcargo Logistics - Trying to stich through an integrated offering - ICICI Securities

Polymer price tracker - Other polymer (ex-PVC) prices too firm up - ICICI Securities

Angel Broking - IPO Review - ICICI Securities

IPO Review - Computer Age Management Services - ICICI Securities

Company Update - EIH Ltd - ICICI Securities

Gladiator Stocks - Godrej Properties - ICICI Securities

Company Update - Dr Reddy's Laboratories - ICICI Securities

Gladiator Stocks: Pharma Thematic - ICICI Securities

Company Update - Housing & Urban Development - ICICI Securities

Covid Recovery Pulse - E-Way bill generation shows recovery signs with auto volumes flat - ICICI Securities

Quant Pick - UltraTech Cement - ICICI Securities

Lupin & Cipla - Positive News - Angel Broking

Sterling and Wilson Solar Ltd - 106.71 MW order win - Angel Broking

Dr. Reddy's Laboratories - Settles Revlimid litigation in US - ICICI Securities

Natco Pharma - Natco to launch first generic Revlimid - ICICI Securities

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019